276 related articles for article (PubMed ID: 36165528)
1. A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma.
Lin L; Wu XH; Zhu JM; Chen SH; Chen YH; Lin F; Xue XY; Wei Y; Xu N; Zheng QS; Sun XL
Comb Chem High Throughput Screen; 2023; 26(8):1503-1518. PubMed ID: 36165528
[TBL] [Abstract][Full Text] [Related]
2. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of necroptosis-related lncRNA signature with potential implications in tumor heterogeneity and prediction of prognosis in clear cell renal cell carcinoma.
Lin H; Qu L; Chen G; Zhang C; Lu L; Chen Y
Eur J Med Res; 2023 Jul; 28(1):236. PubMed ID: 37452355
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
5. A novel coagulation-related lncRNA predicts the prognosis and immune of clear cell renal cell carcinoma.
Wu W; Chang F; Zhang J; Tang S; Lv Z; Chen F
Sci Rep; 2023 Sep; 13(1):16302. PubMed ID: 37770494
[TBL] [Abstract][Full Text] [Related]
6. Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma.
Deng Y; Guo K; Tang Z; Feng Y; Cai S; Ye J; Xi Y; Li J; Liu R; Cai C; Tan Z; Zhang Y; Han Z; Zeng G; Zhong W
Front Immunol; 2022; 13():1046790. PubMed ID: 36505457
[TBL] [Abstract][Full Text] [Related]
7. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
[TBL] [Abstract][Full Text] [Related]
8. Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma.
Wei SY; Feng B; Bi M; Guo HY; Ning SW; Cui R
BMC Med Genomics; 2022 Dec; 15(1):263. PubMed ID: 36528763
[TBL] [Abstract][Full Text] [Related]
9. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
[TBL] [Abstract][Full Text] [Related]
10. Identification and validation of a ferroptosis-related lncRNA signature to robustly predict the prognosis, immune microenvironment, and immunotherapy efficiency in patients with clear cell renal cell carcinoma.
Ju L; Shi Y; Liu G
PeerJ; 2022; 10():e14506. PubMed ID: 36570012
[TBL] [Abstract][Full Text] [Related]
11. Identification of a glycolysis-related lncRNA prognostic signature for clear cell renal cell carcinoma.
Ma W; Zhong M; Liu X
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34402862
[TBL] [Abstract][Full Text] [Related]
12. Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.
Sun JX; Xia QD; Liu CQ; Xu JZ; Xun Y; Lu JL; Hu J; Wang SG
Dis Markers; 2021; 2021():8800358. PubMed ID: 34512816
[TBL] [Abstract][Full Text] [Related]
13. Disulfideptosis-associated lncRNAs reveal features of prognostic, immune escape, tumor mutation, and tumor malignant progression in renal clear cell carcinoma.
Li X; Deng X; Liu T; Zhang W; Tao J
Aging (Albany NY); 2024 Feb; 16(4):3280-3301. PubMed ID: 38334964
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of CCNB2 and a novel lncRNAs-related risk model predict prognosis in clear cell renal cell carcinoma.
Ren C; Wang Q; Xu Z; Pan Y; Wang S; Liu X
J Cancer Res Clin Oncol; 2024 Feb; 150(2):64. PubMed ID: 38300330
[TBL] [Abstract][Full Text] [Related]
15. Exosome-related lncRNA score: A value-based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma.
Yang Z; Zhang X; Zhan N; Lin L; Zhang J; Peng L; Qiu T; Luo Y; Liu C; Pan C; Hu J; Ye Y; Jiang Z; Liu X; Sun M; Zhang Y
Cancer Med; 2024 Jun; 13(11):e7308. PubMed ID: 38808948
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation based on RNA-sequencing data.
Zeng JH; Lu W; Liang L; Chen G; Lan HH; Liang XY; Zhu X
J Transl Med; 2019 Aug; 17(1):281. PubMed ID: 31443717
[TBL] [Abstract][Full Text] [Related]
17. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
Zhang C; Li Z; Qi F; Hu X; Luo J
Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
[TBL] [Abstract][Full Text] [Related]
18. A Novel Immune-Related lncRNA-Based Model for Survival Prediction in Clear Cell Renal Cell Carcinoma.
Zhang Z; Tang Y; Liu Y; Zhuang H; Lin E; Xie L; Feng X; Tian K; Zeng J; Liu J; Yu Y
J Immunol Res; 2021; 2021():9921466. PubMed ID: 34368371
[TBL] [Abstract][Full Text] [Related]
19. Accurate prognostic prediction for patients with clear cell renal cell carcinoma using a ferroptosis-related long non-coding RNA risk model.
Xiang X; Guo Y; Chen Z; Zhang F; Qin Y
Cancer Biomark; 2023; 37(2):95-107. PubMed ID: 37248883
[TBL] [Abstract][Full Text] [Related]
20. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
